Molecular Templates

Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. It utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies, or ETBs. The company was founded by Eric E. Poma, Jean Gariépy, and Leigh Revers in 2000 and is headquartered in Austin, TX.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. It utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies, or ETBs. The company was founded by Eric E. Poma, Jean Gariépy, and Leigh Revers in 2001 and is headquartered in Austin, TX.

AUSTIN, Texas, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, was notified on December 16, 2024 by the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) of the Staff's determination pursuant to Nasdaq Listing Rule 5101 that the Company is a “public shell,” and that, in the view of the Staff, the continued listing of the Company's securities was no longer warranted. Further, Nasdaq indicated that the Company's non-compliance with (i) Nasdaq Listing Rule 5250(c)(1) as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q for the period ended September 30, 2024 and (ii) Nasdaq Listing Rule 5550(a)(2) as a result of its failure to maintain a $1.00 bid price for the required period, each serving as an additional and separate basis for delisting. Trading of the Company's common stock will be suspended at the opening of business on December 26, 2024, and Nasdaq will file a Form 25-NSE with the U.S. Securities and Exchange Commission to formally delist the Company's securities from listing and registration, unless the Company timely requests a hearing before a Nasdaq Hearings Panel to appeal Nasdaq's determination and address the deficiencies. The Company does not plan to request a hearing regarding these deficiencies and expects that trading in the Company's common stock on the Nasdaq Stock Market will be suspended upon the opening of business on December 26, 2024.

Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules

AUSTIN, Texas, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM” or the “Company”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, announced that it has received an expected deficiency notification letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) on November 25, 2024. The notice indicated that MTEM is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) as a result of its failure to timely file its Quarterly Report on Form 10-Q for the period ended September 30, 2024 (the “Form 10-Q”), as described more fully in MTEM's Form 12b-25 Notification of Late Filing (the “Form 12b-25”) filed with the Securities and Exchange Commission (the “SEC”) on November 15, 2024. The Listing Rule requires Nasdaq-listed companies to timely file all required periodic reports with the SEC. MTEM has until January 24, 2025 to submit a plan of compliance with respect to the notice.

Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements

AUSTIN, Texas, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action, today reported financial results and business updates for the second quarter of 2024.

Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update

AUSTIN, Texas, June 03, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage company focused on the discovery and development of targeted biologic therapeutics with unique mechanisms of action (engineered toxin bodies or “ETBs”) for cancer and immune-mediated disease, today provided an update on its clinical-stage programs.

Molecular Templates, Inc. Provides Interim Update

AUSTIN, Texas, May 15, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action, today reported financial results and business updates for the first quarter of 2024.

Molecular Templates, Inc. Reports First Quarter 2024 Financial Results and Corporate Update

AUSTIN, Texas, April 09, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, today announced that MTEM will present a poster, “First-in-human, dose escalation and expansion study of MT-6402, a novel engineered toxin body (ETB) targeting PD-L1, in patients with PD-L1 expressing relapsed/refractory advanced solid tumors: Interim Data,” at the 2024 American Association for Cancer Research Annual Meeting taking place in San Diego, CA, and also announced monotherapy response activity in Head and Neck Cancer.

Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patie

AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

AUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, known as engineered toxin bodies, to create novel therapies with potent and differentiated mechanisms of action for cancer, announced today it has entered into a definitive amended and restated securities purchase agreement with certain healthcare investors that will provide $9.5 million in gross proceeds to MTEM through the closing of the second tranche of its previously announced July 2023 private placement and purchase agreement on amended terms. The financing is being led by existing investor BVF Partners L.P. and includes existing investors BB Biotech AG and Santé, and other leading institutional investors.

Molecular Templates Announces $9.5 Million Private Placement Offering and Agreement to Amend Second Tranche of July 2023 Purchase Agreement

Fractyl Health Inc

Inspire Veterinary Partners Inc

Outset Medical

Pacific Biosciences of California

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks Which Could Rescue Your Portfolio In March - Inspire Veterinary (NASDAQ:IVP), Fractyl Health (NASDAQ:GUTS)

AUSTIN, Texas, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics with potent and differentiated mechanisms of action for cancer, announced participation in the upcoming Oppenheimer 34th Annual Healthcare Life Sciences Conference.

Molecular Templates to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

AUSTIN, Texas, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results and business updates for the third quarter of 2023.

Molecular Templates, Inc. Reports Third Quarter 2023 Financial Results and Business Update

AUSTIN, Texas, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating MT-8421, a novel engineered toxin body targeting CTLA-4, for the treatment of advanced solid tumors.

Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors

AUSTIN, Texas, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (ETBs), to create novel therapies with potent differentiated mechanisms of action for cancer, today announced participation in the following upcoming investor conferences:

Molecular Templates to Participate in Upcoming Investor Conferences

AUSTIN, Texas, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced the appointment of Dr. Maurizio Voi to the role of Chief Medical Officer. Dr. Voi possesses more than 35 years of wide-ranging drug development experience. Dr. Voi will begin his new role on October 2, 2023.

Molecular Templates Announces the Appointment of Dr. Maurizio Voi to the Role of Chief Medical Officer

Molecular Templates Inc. (MTEM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Looking for a Fast-paced Momentum Stock at a Bargain? Consider Molecular Templates Inc. (MTEM)

AUSTIN, Texas, Aug. 11, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc., (Nasdaq: MTEM) (the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced that the Board and stockholders of the Company approved a 1-for-15 reverse stock split of the Company's common stock at a special meeting of the Company held on August 11, 2023. The reverse stock split will take effect after the close of trading on The Nasdaq Capital Market at 5:00 p.m. Eastern Time, on Friday, August 11, 2023. The Company's common stock will open for trading under a new CUSIP number 608550 208 on The Nasdaq Capital Market on August 14, 2023, on a split-adjusted basis under the current ticker symbol "MTEM." The reverse stock split is intended to increase the per share trading price of the Company's common stock to enable the Company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market.

Molecular Templates Announces 1-for-15 Reverse Stock Split

AUSTIN, Texas, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, today reported financial results and business updates for the second quarter of 2023.

Molecular Templates, Inc. Reports Second Quarter 2023 Financial Results and Business Update

AUSTIN, Texas, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced executive management changes to implement its next phase of development. Dr. Gabriela Gruia will assume the role of interim Chief Medical Officer to succeed Dr. Roger Waltzman, Jason Kim will assume the role of President and Chief Financial Officer, Kristen Quigley will assume the role of Chief Operating Officer, and Dr. Grace Kim will assume the role of Chief Strategy Officer and Head of Investor Relations. These appointments were made to better enable Molecular Templates to execute on its clinical and corporate objectives.

Molecular Templates Announces Executive Leadership Changes

AUSTIN, Texas, July 13, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, announced today it has entered into a definitive securities purchase agreement with certain healthcare investors that will provide up to $40 million in gross proceeds to MTEM through a private placement in two tranches. The financing is being led by existing investor BVF Partners LP and includes existing investors BB Biotech AG and Adage Capital Management, and other leading institutional investors.

Molecular Templates Announces Up to $40 Million Private Placement Offering

AUSTIN, Texas, June 16, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, announced today that it has entered into a restructuring agreement (“Amending Agreement”) with K2 HealthVentures (“K2HV”) to satisfy and discharge MTEM's outstanding secured debt obligations and terminate all other obligations under the existing debt financing facility between Molecular Templates and K2HV. Molecular Templates also announced a restructuring plan that includes reducing its current workforce as it continues to explore strategic alternatives.

Molecular Templates Announces Debt Payoff and Restructuring

AUSTIN, Texas, June 01, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, announced today that the U.S. Food and Drug Administration (“FDA”), after reviewing safety data on the program, has removed the partial clinical hold on patient enrollment for its MT-0169 trial, allowing Molecular Templates to proceed with its plan to evaluate the efficacy of MT-0169, one of its ETBs, which specifically targets CD38, a validated target in Multiple Myeloma. The FDA placed the Phase I study for MT-0169 on a partial clinical hold in April 2023, based on previously disclosed asymptomatic and fully reversible cardiac adverse events (“AEs”) noted in two patients dosed at 50 mcg/kg which prompted the dose reduction to 5 mcg/kg last year.

Molecular Templates Announces the FDA Removal of Partial Clinical Hold in the Phase 1 Clinical Trial for MT-0169 and Focuses on Extramedullary Myeloma

AUSTIN, Texas, May 26, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary targeted biologic therapeutics, engineered toxin bodies (“ETBs”), to create novel therapies with potent differentiated mechanisms of action for cancer, announced today the presentation of a poster at the American Society of Clinical Oncology (“ASCO”) Annual Meeting, taking place June 2-6, 2023 in Chicago, IL. One-on-one meetings may be scheduled directly with Molecular Templates.

Molecular Templates to Present on Phase I Dose Escalation Study of MT-6402 at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Advancing clinical development of MT-6402, MT-8421, and MT-0169, and preclinical activities related to Bristol Myers Squibb collaboration

Molecular Templates, Inc. Reports First Quarter 2023 Financial Results and Business Update

Molecular Templates Inc. (MTEM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Molecular Templates Inc. (MTEM) Report Negative Q1 Earnings? What You Should Know

Partial hold based on previously disclosed cardiac events at 50 mcg/kg cohort; FDA to review safety data in lower dose cohorts Partial hold based on previously disclosed cardiac events at 50 mcg/kg cohort; FDA to review safety data in lower dose cohorts

News for Molecular Templates Stock (MTEM)